ImageneBio, Inc. (IMA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45175G2075
ImageneBio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 800,000.00 USD |
| Operating income | -48.45 m USD |
| EBIT | -45.70 m USD |
| Net income | -45.35 m USD |
| Diluted EPS – continuing operations | -9.64 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
More stocks
- Eltek Ltd (ELTK)
- Cytogen Inc (217330.KQ)
- DK Life Science Co., Ltd. (303810.KQ)
- Castellum, Inc. (CTM)
- Innometry Co. Ltd (302430.KQ)
- Namib Minerals Ordinary Shares (NAMM)
- M2I Corporation (347890.KQ)
- Aptera Motors Corp (SEV)
- Foxwell Power Co., Ltd. (6994.TW)
- Forward Science Corp. (7530.TWO)
- FUEL TECH, INC. (FTEK)
- C-SITE Co., Ltd. (109670.KQ)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.